NCT06912087 2025-12-02
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Phase 1 Recruiting
University of Chicago
AVEO Pharmaceuticals, Inc.
University of Pittsburgh
Gruppo Oncologico del Nord-Ovest